The proposed TRIPs covid waiver is a bad idea that could do a lot of good
The Long Read: With Big Pharma being blamed for the slow roll-out of vaccines in medium and low-income countries, Zilber IP’s Einav Zilber argues that the debate over suspending patents, trade secrets and other rights to increase access to jabs is really about the relationship between states and drug companies – and that these issues are not going away
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.